Sandusky, Ohio–(Newsfile Corp. – September 17, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today highlighted recent increased interest in the resurgence of industry wide pharmaceutical research and manufacturing in Puerto Rico.
US Relies on China for a High Percentage of Pharmaceuticals
To view an enhanced version of this graphic, please visit:
Packaging Industry Digest described the current state of Puerto Rico’s pharmaceutical industry reboot: “Puerto Rico still has a vibrant pharmaceutical industry. Many top global companies – Amgen, Eli Lilly, Bristol-Myers Squibb, Johnson & Johnson, Merck, Abbvie, Pfizer, Glaxo, and others – have major facilities here. Some have more than one plant. Companies – such as Boehringer-Ingleheim, Glaxo, Romark, and others – are setting up shop or returning to the Commonwealth. Others are expanding existing facilities.”
Tomorrow, Friday, September 18, 2020, PAOG CEO James C. DiPrima will discuss in an interview with Donald Baillargeon of MoneyTV, PAOG’s overall approach to engaging a Contract Research Organization (CRO) to advance an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for PAOG’s RespRx as a COPD treatment.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
Powered by WPeMatico